Dashboard
Manage Tickers

XNCR


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

xencor-presents-initial-results-from-ongoing-phase-1-dose-escalation-study-of-xmab819-enpp3-x-cd3-t-cell-engaging-bispecific-antibody-in-patients-with-advanced-ccrcc-at-aacr-nci-eortc
Xencor Presents Initial Results From Ongoi...
10/24/2025 16:31:47

-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 17:06:11

xencor-to-present-initial-results-from-ongoing-phase-1-dose-escalation-study-of-xmab819-in-patients-with-ccrcc-at-aacr-nci-eortc-conference-2025
Xencor To Present Initial Results From Ong...
10/14/2025 16:47:31

-- Management to host webcast and conference call on Friday, October 24, 2025 --Xencor, Inc. (NASDAQ:XNCR), a clinical-stage bi...

cantor-fitzgerald-assumes-xencor-at-overweight-announces-price-target-of-40
Cantor Fitzgerald Assumes Xencor at Overwe...
10/06/2025 13:30:39

Cantor Fitzgerald analyst Steve Seedhouse assumes Xencor (NASDAQ:XNCR) with a Overweight rating and announces Price Target o...

b-of-a-securities-downgrades-xencor-to-neutral-lowers-price-target-to-12
B of A Securities Downgrades Xencor to Neu...
09/03/2025 15:51:39

B of A Securities analyst Alec Stranahan downgrades Xencor (NASDAQ:XNCR) from Buy to Neutral and lowers the price target fro...

beyond-the-numbers-4-analysts-discuss-xencor-stock
Beyond The Numbers: 4 Analysts Discuss Xen...
09/02/2025 21:00:21

wedbush-reiterates-outperform-on-xencor-maintains-26-price-target
Wedbush Reiterates Outperform on Xencor, M...
09/02/2025 15:20:01

Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $26 price target.

rbc-capital-maintains-outperform-on-xencor-lowers-price-target-to-15
RBC Capital Maintains Outperform on Xencor...
08/21/2025 14:17:06

RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $32 to...

wells-fargo-maintains-overweight-on-xencor-lowers-price-target-to-27
Wells Fargo Maintains Overweight on Xencor...
08/07/2025 14:47:12

Wells Fargo analyst Eva Fortea Verdejo maintains Xencor (NASDAQ:XNCR) with a Overweight and lowers the price target from $33...

wedbush-maintains-outperform-on-xencor-lowers-price-target-to-26
Wedbush Maintains Outperform on Xencor, Lo...
08/07/2025 12:39:42

Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $31 to ...

xencor-q2-eps-041-beats-072-estimate-sales-4361m-beat-2145m-estimate
Xencor Q2 EPS $(0.41) Beats $(0.72) Estima...
08/06/2025 20:43:03

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.72) by 43....

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
05/09/2025 21:06:23

barclays-maintains-underweight-on-xencor-lowers-price-target-to-6
Barclays Maintains Underweight on Xencor, ...
05/08/2025 16:43:02

Barclays analyst Peter Lawson maintains Xencor (NASDAQ:XNCR) with a Underweight and lowers the price target from $22 to $6.

xencor-q1-eps-066-misses-060-estimate-sales-3273m-beat-2241m-estimate
Xencor Q1 EPS $(0.66) Misses $(0.60) Estim...
05/07/2025 20:50:22

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.60) by 1...

Core News & Articles
'FDA Names Vinay Prasad as New Head of Vac...
05/06/2025 17:53:23

https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics

xencor-announces-positive-interim-results-from-first-in-human-healthy-volunteer-study-of-xmab942-a-high-potency-extended-half-life-anti-tl1a-antibody-for-treatment-of-inflammatory-bowel-disease
Xencor Announces Positive Interim Results ...
04/29/2025 20:02:44

-- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 ---- Sin...

william-blair-initiates-coverage-on-xencor-with-outperform-rating
William Blair Initiates Coverage On Xencor...
04/21/2025 15:24:09

William Blair analyst Matt Phipps initiates coverage on Xencor (NASDAQ:XNCR) with a Outperform rating.

wells-fargo-maintains-overweight-on-xencor-lowers-price-target-to-33
Wells Fargo Maintains Overweight on Xencor...
02/28/2025 17:22:44

Wells Fargo analyst Eva Fortea Verdejo maintains Xencor (NASDAQ:XNCR) with a Overweight and lowers the price target from $37...

xencor-q4-eps-062-beats-078-estimate-sales-5279m-beat-1948m-estimate
Xencor Q4 EPS $(0.62) Beats $(0.78) Estima...
02/27/2025 13:14:27

Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.78) by 20....

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
02/06/2025 12:05:47

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION